Display options
Cite
MacIntyre I, Stevenson JC, Whitehead MI, et al. Calcitonin for prevention of postmenopausal bone loss. Lancet. 1988;1(8591):900-2doi: 10.1016/s0140-6736(88)91712-6.
MacIntyre, I., Stevenson, J. C., Whitehead, M. I., Wimalawansa, S. J., Banks, L. M., & Healy, M. J. (1988). Calcitonin for prevention of postmenopausal bone loss. Lancet (London, England), 1(8591), 900-2. https://doi.org/10.1016/s0140-6736(88)91712-6
MacIntyre, I, et al. "Calcitonin for prevention of postmenopausal bone loss." Lancet (London, England) vol. 1,8591 (1988): 900-2. doi: https://doi.org/10.1016/s0140-6736(88)91712-6
MacIntyre I, Stevenson JC, Whitehead MI, Wimalawansa SJ, Banks LM, Healy MJ. Calcitonin for prevention of postmenopausal bone loss. Lancet. 1988 Apr 23;1(8591):900-2. doi: 10.1016/s0140-6736(88)91712-6. PMID: 2895829.
Copy Download .nbib Format: NLM
Share it on
Full text links
Elsevier Science

Lancet. 1988 Apr 23;1(8591):900-2. doi: 10.1016/s0140-6736(88)91712-6.

Calcitonin for prevention of postmenopausal bone loss.

Lancet (London, England)

I MacIntyre, J C Stevenson, M I Whitehead, S J Wimalawansa, L M Banks, M J Healy

Affiliations

  1. Endocrine Unit, Royal Postgraduate Medical School, London.

PMID: 2895829 DOI: 10.1016/s0140-6736(88)91712-6

Abstract

A 2-year randomised pilot study was conducted in 70 patients to see whether the osteoclast-inhibiting effect of calcitonin would reduce postmenopausal vertebral bone loss. An oestradiol-treated group was included in the study as a positive control since oestrogens are known to be effective. Calcitonin reduced vertebral bone loss in doses above 250 micrograms human calcitonin (50 international units) a week, and at this dose was as effective as oestradiol.

Cited by

Substances

MeSH terms

Publication Types

LinkOut - more resources